Previous close | 7.89 |
Open | 7.95 |
Bid | 7.39 x 600 |
Ask | 7.42 x 600 |
Day's range | 7.35 - 7.95 |
52-week range | 2.09 - 14.84 |
Volume | |
Avg. volume | 4,320,033 |
Market cap | 523.967M |
Beta (5Y monthly) | 0.20 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.60 |
Earnings date | 08 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 20 Jan 2017 |
1y target est | 20.57 |
Roundhill Investments, an ETF sponsor focused on innovative financial products, is pleased to announce the launch of the Roundhill GLP-1 & Weight Loss ETF (OZEM), which began trading on Nasdaq today. OZEM is the world's first ETF focused exclusively on the rapidly growing sector of GLP-1 receptor agonists and other weight management drugs.
Altimmune ( NASDAQ:ALT ) First Quarter 2024 Results Key Financial Results Net loss: US$24.4m (loss widened by 22% from...
Enrollment ongoing in IMPACT Phase 2b trial of pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH), with top line results expected in Q1 2025 Cash, cash equivalents and short-term investments of $182.1 million at March 31, 2024 Webcast to be held today, May 9, 2024, at 8:30 am ET GAITHERSBURG, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2